Epidemiology and antifungal resistance in invasive candidiasis

European Journal of Medical Research

Volumn 16, Issue 4, 2011, Pages 187-195

  Rodloff, Arne C ^a   Koch, D ^a   Schaumann, R ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE; AMPHOTERICIN; STEROL;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOODSTREAM INFECTION; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; CAUSE OF DEATH; DISK DIFFUSION; DRUG MECHANISM; HUMAN; INCIDENCE; INVASIVE CANDIDIASIS; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MYCOSIS; NONHUMAN; UNITED STATES; DRUG EFFICACY; FUNGAL GENETICS; FUNGUS ISOLATION; LIPOGENESIS; MOLECULAR EPIDEMIOLOGY; REVIEW;

EID: 79955803465     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-16-4-187     Document Type: Article

References (42)

1. Michael M. McNeil, Stephanie L. Nash, Rana A. Hajjeh, Maureen A. Phelan, Laura A. Conn, Brian D. Plikaytis, and David W. Warnock. 2001. Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980-1997. Clin Infect Dis 33(5): 641-647
2. Beck-Sague, C. and W. R. Jarvis. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J Infect Dis 167:1247-1251.
3. Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N. & Wenzel, R. P. (1999). Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29, 239-244. (Pubitemid 29380177)
4. Lamagni TL, Evans BG, Shigematsu M, Johnson EM. 2001. Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9). Epidemiol Infect 126(3):397-414. (Pubitemid 32640703)
5. Eggimann, P., Garbino, J. & Pittet, D. 2003. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis 3, 685-702. (Pubitemid 37345347)
6. Washton H. 1989. Review of fluconazole: a new triazole antifungal agent. Diagn Microbiol Infect Dis 12(4 Suppl): 229S-233S.
7. Olivier Leroy, MD; Jean-Pierre Gangneux, MD, PhD; Philippe Montravers, MD, PhD;Jean-Paul Mira, MD, PhD; François Gouin, MD; Jean-Pierre Sollet, MD; Jean Carlet, MD; Jacques Reynes, MD, PhD; Michel Rosenheim, MD; Bernard Regnier, MD, PhD; Olivier Lortholary, MD, PhD; for the AmarCand Study Group. 2009. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005-2006). Crit Care Med 37 (5), 1612-18
8. M. A. Pfaller and D. J. Diekema. 2007. Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin Microbiol Rev 20 (1): 133-163
9. M. A. Pfaller, D. J. Diekema, D. L. Gibbs, V. A. Newell, D. Ellis, V. Tullio, A. Rodloff, W. Fu, T. A. Ling, and the Global Antifungal Surveillance Group. 2010. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion. J Clin Microbiol. 48 (4) 1366-1377
10. Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. 2011. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother 55(2):561-6.
11. David L. Horn, Dionissios Neofytos, Elias J. Anaissie, Jay A. Fishman, William J. Steinbach, Ali J. Olyaei, Kieren A. Marr, Michael A. Pfaller, Chi-Hsing Chang, and Karen M. Webster. 2009. Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry. Clin Infect Dis 48:1695-703
12. Luis Ostrosky-Zeichner, John H. Rex, Peter G. Pappas, Richard J. Hamill, Robert A. Larsen, Harold W. Horowitz, William G. Powderly, Newton Hyslop, Carol A. Kauffman, John Cleary, Julie E. Mangino, and Jeannette Lee. 2003. Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States. Antimicrob Agents Chemother 47 (10) 3149-3154
13. R. Cisterna, G. Ezpeleta, O. Telleria, J. Guinea, B. Regueiro, J. Garcia-Rodríguez, J. Esperalba, and The Spanish Candidemia Surveillance Group. 2010. Nationwide Sentinel Surveillance of Bloodstream Candida Infections in 40 Tertiary Care Hospitals in Spain. J Clin Microbiol 48 (11), 4200-4206
14. Arendrup MC, Bruun B, Christensen JJ, Fuursted K, Johansen HK, Kjaeklgaard P, Knudsen JD Kristensen L, Møller J, Nielsen L, Rosenvinge FS, Roder B, Schønheyder HC, Thomsen MK, Truberg K. 2011. National surveillance of fungemia in Denmark (2004-2009). J Clin Microbiol 49 (1), 325-34
15. Ralf Fleck, Annebärbel Dietz and Herbert Hof. 2007. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference brothmicrodilution method and Etest. J Antimicrob Chemother 59, 767-771
16. Borg-von Zepelin M, Kunz L, Rüchel R, Reichard U, Weig M, Gross U. 2007. Epidemiology and antifungal susceptibilities of Candida spp. to six antifungal agents: results from a surveillance study on fungaemia in Germany from July 2004 to August 2005. J Antimicrob Chemother 60 (2):424-8 (Pubitemid 47243899)
17. M27-A3, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard - Third Edition 2008, Clinical and Laboratory Standards Institute, Wayne, USA
18. M44A2, Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Guideline-Second Edition 2009, Clinical and Laboratory Standards Institute, Wayne, USA
19. Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST). 2008. EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 14: 398-405
20. Manuel Cuenca-Estrella, Wendy Lee-Yang, Meral A. Ciblak, Beth A. Arthington-Skaggs Emilia Mellado, David W. Warnock, and Juan L. Rodriguez-Tudela. 2002. Comparative Evaluation of NCCLS M27-A and EUCAST Broth Microdilution Procedures for Antifungal Susceptibility Testing of Candida Species. Antimicrob Agents Chemother 46 (11): 3644-3647
21. A. Espinel-Ingroff, F. Barchiesi, M. Cuenca-Estrella, M. A. Pfaller, M. Rinaldi, J. L. Rodriguez-Tudela, and P. E. Verweij. 2005. International and Multicenter Comparison of EUCAST and CLSI M27-A2 Broth Microdilution Methods for Testing Susceptibilities of Candida spp. to Fluconazole, Itraconazole, Posaconazole, and Voriconazole. J Clin Microbiol 43 (8): 3884-3889
22. Maiken Cavling Arendrup, Guillermo Garcia-Effron, Cornelia Lass-Flörl, Alicia Gomez Lopez, Juan-Luis Rodriguez-Tudela, Manuel Cuenca-Estrella, and David S. Perlin. 2010. Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media. Antimicrob Agents Chemother 54 (1): 426-439
23. M. A. Pfaller, M. Castanheira, D. J. Diekema, S. A. Messer, G. J. Moet, and R. N. Jones. 2010. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest Methods with the CLSI Broth Microdilution Method for Echinocandin Susceptibility Testing of Candida Species. J Clin Microbiol 48 (5): 1592-1599
24. Manuel Cuenca-Estrella, Alicia Gomez-Lopez, Ana Alastruey-Izquierdo, Leticia Bernal-Martinez, Isabel Cuesta, Maria J. Buitrago, and Juan L. Rodriguez-Tudela. 2010. Comparison of the VITEK 2 Antifungal Susceptibility System with the CLSI and the EUCAST Broth Microdilution Reference Methods and with the Sensititre Yeast-One and the Etest Techniques for the Detection in Vitro of Antifungal Resistance in Yeasts. J Clin Microbiol 48: 1782-1786.
25. Maiken Cavling Arendrup, Gunnar Kahlmeter, Juan Luis Rodriguez-Tudela, and J. Peter Donnelly. 2009. Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species. Antimicrobial Agents Chemother 53(4): 1628-1629
26. Morschhäuser J (2002) The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 1587: 240-248.
27. Park S, Kelly R, Kahn JN, J. Robles, M.-J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 49 (8): 3264-73.
28. Balashov SV, Park S, Perlin DS. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother 50: 2058-63. (Pubitemid 43807526)
29. Manjunath P. Pai,1 Robin S. Turpin,2,3 and Kevin W. Garey. 2007. Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia. Antimicrob Agents Chemother 51 (1): 35-39
30. Hernandez S, Lopez-Ribot JL, Najvar LK, Dora I. McCarthy, Rosie Bocanegra, and John R. Graybill. 2004. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratorysusceptibility testing of three isogenic isolates serially obtainedfrom a patient with progressive Candida esophagitis. Antimicrob Agents Chemother 48: 1382-3.
31. Katiyar S, Pfaller M, Edlind T. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother 50: 2892-4. (Pubitemid 44198725)
32. Laverdiere M, Lalonde RG, Baril JG, Donald C. Sheppard, Steven Park, and David S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 57: 705-8.
33. Miller CD, Lomaestro BW, Park S, David S. Perlin. 2006. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26: 877-80.
34. Hakki M, Staab JF, Marr KA. 2006. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 50: 2522-4. (Pubitemid 43993195)
35. Krogh-Madsen M, Arendrup MC, Heslet L, Jenny Dahl Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 42: 938-44.
36. Maiken C. Arendrup, Manuel Cuenca-Estrella, J. Peter Donnelly, Cornelia Lass-Flörl, Juan L. Rodriguez-Tudela. 2009.Association of Fluconazole Pharmacodynamics with Mortality in Patients with Candidemia. Antimicrob Agents Chemother 53 (6) 2704-2705
37. John W. Baddley, Luis Ostrosky-Zeichner, Sujata M. Bhavnani, David R. Andes. 2009. Authors' Reply. Antimicrob Agents Chemother 53 (6) 2705-2706
38. M. A. Pfaller, L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2008. In Vitro Susceptibility of Invasive Isolates of Candida spp. To Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance. J Clin Microbiol 46 (1): 150-156
39. Shawn A. Messer, Gary J. Moetl Jeffrey T. Kirby, and Ronald N. Jones. 2009. Activity of Contemporary Antifungal Agents, Including the Novel Echinocandin Anidulafungin, Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol 47 (6): 1942-1946
40. Shawn A. Messer, Ronald N. Jones, Gary J. Moet, Jeffrey T. Kirby, and Mariana Castanheira. 2010. Potency of Anidulafungin Compared to Nine Other Antifungal Agents Tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: Results from the Global SENTRY Antimicrobial Surveillance Program (2008). J Clin Microbiol 48 (8): 2984-2987
41. D. J. Diekema, S. A. Messer, L. B. Boyken, R. J. Hollis, J. Kroeger, S. Tendolkar, and M. A. Pfaller. 2009. In Vitro Activity of Seven Systemically Active Antifungal Agents against a Large Global Collection of Rare Candida Species as Determined by CLSI Broth Microdilution Methods. J Clin Microbiol 47 (10): 3170-3177
42. S. C. A. Chen, D. Marriott, E. G. Playford, Q. Nguyen, D. Ellis, W. Meyer, T. C. Sorrell, M. Slavin and the Australian Candidaemia Study. 2009. Candidaemia with uncommon Candida species: predisposing factors,outcome, antifungal susceptibility, and implications for management. Clin Microbiol Infect 15: 662-669